secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2022-09-02T23:59:59+00:00
Accession:  0000939767-22-000101
Event type: litigation
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis files second patent infringement suit against Teva over generic CABOMETYX
--------------------------------------------------------------------------------

- Exelixis filed complaint against Teva for infringing U.S. Patent No. 11,298,349 covering CABOMETYX (cabozantinib) tablets.
- Teva filed ANDA with Paragraph IV certification; Exelixis seeks injunction and FDA approval delay until patent expires Feb 10, 2032.
- This is the second case; first case (2021) is stayed administratively, asserting three other patents expiring July 9, 2033.
- No trial scheduled yet; Exelixis seeks equitable relief to block Teva's generic launch before patent expiration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976722000101/0000939767-22-000101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976722000101/exel-20220902.htm
  HTML page:      https://secwatch.observer/filing/0000939767-22-000101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer